Examinando por Materia "Anticuerpos Monoclonales"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 1 de 1
  • Miniatura
    PublicaciónAcceso abierto
    Consumo de anticuerpos monoclonales en la unidad de mezclas oncológicas del Hospital Santa Rosa. Lima 2022
    (Universidad Privada Norbert Wiener, 2022-11-02) Sulca Jara, Jesús Napoleón; Caldas Herrera, Emma
    Objective: To evaluate the consumption of monoclonal antibodies in the oncology mixing unit of Hospital Santa Rosa Lima, 2022. Method: This study has a quantitative approach, basic type, observational, cross-sectional, and retrospective design. It was applied to a sample of 245 treatment regimens. The instrument used was data collection sheets where all the information obtained from the chemotherapy regimens was recorded. The results were clear, aligned with the objectives, and supported by the bibliography. Results: The consumption of trastuzumab 440 mg was 97 vials, rituximab 100 mg was 43 vials, rituximab 500 mg was 20 vials, cetuximab 100 mg was 27 vials, and pertuzumab 420 mg was 4 vials dispensed. Cost results showed that trastuzumab 440 mg had the highest value at S/ 509,529.36, while the 6-month cost of rituximab 100 mg was S/ 197,748.40, rituximab 500 mg was S/ 48,607.60, cetuximab 100 mg was S/ 27,216.00, and pertuzumab 420 mg was S/ 29,732.00. Returns showed the highest index for trastuzumab 440 mg with 17 units returned during the 6-month study period, followed by rituximab 500 mg with 3 units. Savings results indicated that trastuzumab 440 mg achieved savings of S/ 89,298.96, and rituximab 500 mg achieved savings of S/ 7,291.14. Conclusion: The total consumption of vials from January to June 2022 was 191, with a total cost of S/. 812,833.36 soles, generating total returns of 20 vials, equivalent to savings of S/ 96,590.10 during this period.